125 related articles for article (PubMed ID: 36561177)
1. Analysis and comparison of SARS-CoV-2 variant antibodies and neutralizing activity for 6 months after a booster mRNA vaccine in a healthcare worker population.
Khan S; Hosseinian S; Assis R; Khalil G; Luu M; Jain A; Horvath P; Nakajima R; Palma A; Hoang A; Razzak E; Garcia N; Alger J; Kalantari M; Silzel E; Jasinskas A; Zaldivar F; Schubl S; Felgner P
Res Sq; 2022 Dec; ():. PubMed ID: 36561177
[TBL] [Abstract][Full Text] [Related]
2. Analysis and comparison of SARS-CoV-2 variant antibodies and neutralizing activity for 6 months after a booster mRNA vaccine in a healthcare worker population.
Hosseinian S; de Assis R; Khalil G; Luu MK; Jain A; Horvath P; Nakajima R; Palma AM; Hoang A; Razzak E; Garcia N; Alger J; Kalantari M; Silzel EK; Jasinskas A; Zaldivar F; Schubl SD; Felgner PL; Khan S
Front Immunol; 2023; 14():1166261. PubMed ID: 37266444
[TBL] [Abstract][Full Text] [Related]
3. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial.
Corominas J; Garriga C; Prenafeta A; Moros A; Cañete M; Barreiro A; González-González L; Madrenas L; Güell I; Clotet B; Izquierdo-Useros N; Raïch-Regué D; Gallemí M; Blanco J; Pradenas E; Trinité B; Prado JG; Blanch-Lombarte O; Pérez-Caballero R; Plana M; Esteban I; Pastor-Quiñones C; Núñez-Costa X; Taleb RA; McSkimming P; Soriano A; Nava J; Anagua JO; Ramos R; Lluch RM; Comes AC; Romero SO; Gomez XM; Sans-Pola C; Moltó J; Benet S; Bailón L; Arribas JR; Borobia AM; Parada JQ; Navarro-Pérez J; Forner Giner MJ; Lucas RO; Jiménez MDMV; Compán SO; Alvarez-Mon M; Troncoso D; Arana-Arri E; Meijide S; Imaz-Ayo N; García PM; de la Villa Martínez S; Fernández SR; Prat T; Torroella È; Ferrer L
Lancet Reg Health Eur; 2023 May; 28():100613. PubMed ID: 37131861
[TBL] [Abstract][Full Text] [Related]
5. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
6. Waning of specific antibodies against Delta and Omicron variants five months after a third dose of BNT162b2 SARS-CoV-2 vaccine in elderly individuals.
Goh YS; Rouers A; Fong SW; Zhuo NZ; Hor PX; Loh CY; Huang Y; Neo VK; Kam IKJ; Wang B; Ngoh EZX; Salleh SNM; Lee RTC; Pada S; Sun LJ; Ong DLS; Somani J; Lee ES; ; ; Maurer-Stroh S; Wang CI; Leo YS; Ren EC; Lye DC; Young BE; Ng LFP; Renia L
Front Immunol; 2022; 13():1031852. PubMed ID: 36451833
[TBL] [Abstract][Full Text] [Related]
7. Comparison of total and neutralizing SARS-CoV-2 spike antibodies against omicron and other variants in paired samples after two or three doses of mRNA vaccine.
Debes AK; Xiao S; Egbert ER; Caturegli P; Sitaras I; Pekosz A; Milstone AM
medRxiv; 2022 Jan; ():. PubMed ID: 35132427
[TBL] [Abstract][Full Text] [Related]
8. Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort.
Itamochi M; Yazawa S; Inasaki N; Saga Y; Yamazaki E; Shimada T; Tamura K; Maenishi E; Isobe J; Nakamura M; Takaoka M; Sasajima H; Kawashiri C; Tani H; Oishi K
Vaccine; 2023 Mar; 41(13):2234-2242. PubMed ID: 36858871
[TBL] [Abstract][Full Text] [Related]
9. Durability of the Neutralizing Antibody Response to mRNA Booster Vaccination Against SARS-CoV-2 BA.2.12.1 and BA.4/5 Variants.
Qu P; Faraone JN; Evans JP; Zheng YM; Carlin C; Lozanski G; Saif LJ; Oltz EM; Gumina RJ; Liu SL
bioRxiv; 2022 Jul; ():. PubMed ID: 35898337
[TBL] [Abstract][Full Text] [Related]
10. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.
Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC
Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863
[TBL] [Abstract][Full Text] [Related]
11. Durability and Immunogenicity of Neutralizing Antibodies Response Against Omicron Variants After Three Doses of Subunit SARS-CoV-2 Vaccine MVC-COV1901: An Extension to an Open-Label, Dose-Escalation Phase 1 Study.
Hsieh SM; Chang SC; Cheng HY; Shih SR; Lien CE
Infect Dis Ther; 2022 Aug; 11(4):1493-1504. PubMed ID: 35579840
[TBL] [Abstract][Full Text] [Related]
12. Neutralizing Antibodies against the SARS-CoV-2 Delta and Omicron BA.1 following Homologous CoronaVac Booster Vaccination.
Li J; Li X; Wang E; Yang J; Li J; Huang C; Zhang Y; Chen K
Vaccines (Basel); 2022 Dec; 10(12):. PubMed ID: 36560521
[TBL] [Abstract][Full Text] [Related]
13. Rapid Evaluation of Vaccine Booster Effectiveness against SARS-CoV-2 Variants.
Cheng HL; Lim SM; Jia H; Chen MW; Ng SY; Gao X; Somani J; Sengupta S; Tay DMY; Chua PWL; R A; Ling SYH; McBee ME; Young BE; Sikes HD; Preiser PR
Microbiol Spectr; 2022 Oct; 10(5):e0225722. PubMed ID: 36069616
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal kinetics of neutralizing antibodies against circulating SARS-CoV-2 variants and estimated level of group immunity of booster-vaccinated individuals during omicron-dominated COVID-19 outbreaks in the Republic of Korea, 2022.
Lee YJ; Choi JY; Yang J; Baek JY; Kim HJ; Kim SH; Jeong H; Kim MS; Lee HW; Kang G; Chung EJ; Kim TY; Hong HJ; Lee SE; Jang YG; Kim SS; Peck KR; Ko JH; Kim B
Microbiol Spectr; 2023 Sep; 11(5):e0165523. PubMed ID: 37750684
[TBL] [Abstract][Full Text] [Related]
15. Omicron neutralizing antibody response following booster vaccination compared with breakthrough infection.
Curlin ME; Bates TA; Guzman G; Schoen D; McBride SK; Carpenter SD; Tafesse FG
Med; 2022 Dec; 3(12):827-837.e3. PubMed ID: 36198311
[TBL] [Abstract][Full Text] [Related]
16. Dynamics of Antibody and T Cell Immunity against SARS-CoV-2 Variants of Concern and the Impact of Booster Vaccinations in Previously Infected and Infection-Naïve Individuals.
Faas MR; Mak WA; Markus HY; van der Zwan EM; van der Vliet M; Koeleman JGM; Ong DSY
Vaccines (Basel); 2022 Dec; 10(12):. PubMed ID: 36560542
[TBL] [Abstract][Full Text] [Related]
17. Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination.
Assawakosri S; Kanokudom S; Chansaenroj J; Suntronwong N; Auphimai C; Nilyanimit P; Vichaiwattana P; Thongmee T; Duangchinda T; Chantima W; Pakchotanon P; Srimuan D; Thatsanatorn T; Klinfueng S; Sudhinaraset N; Mongkolsapaya J; Wanlapakorn N; Honsawek S; Poovorawan Y
Int J Infect Dis; 2022 Sep; 122():793-801. PubMed ID: 35863731
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of the neutralizing antibodies after the booster dose on SARS-CoV-2 Omicron variant and a two-year longitudinal antibody study on Wild Type convalescents.
Zheng Y; Pan J; Jin M; Wang J; Tung TH; Chen S; Bi X; Zhou K; Chen M; Wang D; Li J; Shen B; Ying L
Int Immunopharmacol; 2023 Jun; 119():110151. PubMed ID: 37044040
[TBL] [Abstract][Full Text] [Related]
19. Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based, prospective, longitudinal cohort study.
Bruel T; Pinaud L; Tondeur L; Planas D; Staropoli I; Porrot F; Guivel-Benhassine F; Attia M; Pelleau S; Woudenberg T; Duru C; Koffi AD; Castelain S; Fernandes-Pellerin S; Jolly N; De Facci LP; Roux E; Ungeheuer MN; Van Der Werf S; White M; Schwartz O; Fontanet A
EClinicalMedicine; 2022 Sep; 51():101576. PubMed ID: 35891947
[TBL] [Abstract][Full Text] [Related]
20. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
